Chongqing Precision Biotech

A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents

Started: 1/26/2022

PIC1 Injection Therapy for Relapsed/Refractory B-NHL

Started: 3/1/2026

Study of CD19 CAR-T Therapy for Refractory SLE

Started: 2/1/2026

Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE

Started: 1/26/2026

Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE

Started: 1/1/2026

Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE

Started: 6/12/2025

In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies

Started: 7/1/2025

CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors

Started: 9/12/2025

CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors

Started: 9/12/2025

Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases

Started: 9/1/2025

Clinical Study on Chimeric Antigen Receptor T Lymphocyte (CAR-T) Targeting CEA for the Treatment of CEA - Positive Advanced Lung Cancer

Started: 4/28/2025

Targeted Anti-CEA CAR-T Immunotherapy for Advanced Lung Cancer

Started: 5/8/2025

Anti-CEA CAR-T for Advanced CEA-Positive Lung Carcinoma

Started: 3/24/2025

Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies

Started: 3/27/2025

BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

Started: 4/1/2019

a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

Started: 3/7/2021

a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL

Started: 3/7/2021

A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer

Started: 12/12/2024

Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN

Started: 11/13/2024

Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refractory Juvenile Dermatomyositis (RJDM)

Started: 11/11/2024

Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis

Started: 7/2/2024

CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors

Started: 9/7/2023

A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer

Started: 1/10/2024

Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma

Started: 12/31/2023

Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors

Started: 11/6/2023

Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors

Started: 9/30/2023

A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Started: 11/30/2023

Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease

Started: 8/31/2023

A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors

Started: 8/11/2023

Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm

Started: 8/31/2023